Taking together these findings, USP22 might be maintained at relatively low levels in malignant HCC cells and is markedly increased under long-term sorafenib treatment as a strategy to overcome cell death induced by sorafenib treatment. The gene discussed is USP22; the disease is hepatocellular carcinoma.